Linagliptin Krka (Linagliptin)

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus, acting on the incretin pathway to regulate blood glucose.

• Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels by enhancing insulin secretion and suppressing glucagon.
• Type 2 diabetes mellitus (add‑on therapy): provides additional glycaemic control when combined with metformin or other oral agents.
• Adjunct to diet and exercise: supports lifestyle measures aimed at achieving target HbA1c.

• Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), preventing the breakdown of incretin hormones GLP‑1 and GIP. Elevated incretin levels enhance glucose‑dependent insulin secretion from pancreatic β‑cells and reduce glucagon release from α‑cells, resulting in improved post‑prandial and fasting glucose regulation without causing hypoglycaemia in the absence of other glucose‑lowering agents.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nasopharyngitis: mild inflammation of the nasal passages and throat.
• Headache: transient cranial discomfort.
• Upper respiratory tract infection: symptoms such as cough and sore throat.
• Dizziness: occasional light‑headedness.
• Gastrointestinal upset: nausea or abdominal discomfort.
• Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain with elevated enzymes.
• Severe hypersensitivity: rash, angioedema, or anaphylaxis.
• Bullous pemphigoid: blistering skin disorder.
• Hepatic injury: jaundice or elevated liver enzymes.
• Acute renal failure: sudden decline in kidney function.
• Cardiovascular events: rare reports of heart failure exacerbation.

Linagliptin should be used with awareness of specific safety considerations.

• Renal impairment: assess kidney function before initiating therapy.
• Hepatic impairment: monitor liver enzymes in patients with liver disease.
• Concomitant sulfonylureas or insulin: adjust dose to reduce hypoglycaemia risk.
• History of pancreatitis: avoid use or discontinue if symptoms recur.
• Known hypersensitivity: do not use in patients with documented allergy to linagliptin.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Linagliptin may interact with other medicines, requiring vigilance.

Major Interactions (Avoid)

• Insulin or sulfonylureas: increased risk of severe hypoglycaemia; avoid combination without dose adjustment.
• Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce linagliptin exposure and efficacy.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin plasma levels.

• Diuretics: may affect renal clearance, requiring renal function monitoring.
• ACE inhibitors or ARBs: monitor blood pressure and renal function when used together.
• Anticoagulants: observe for any changes in coagulation parameters.